CIK 0000771856 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 04/30
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue (USD) | 59.4 M | 50.2 M | 53.9 M | |
| Net income (USD) | -5.3 M | 548000 | ||
| Diluted EPS (USD/shares) | -0.08 | -0.54 | -0.39 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | 4 | FORM 4 | 2026-10-15 |
| 2026-10-16 | 8-K | 8-K items 5.07 | 2026-10-14 |
| 2026-09-11 | 10-Q | 10-Q | 2026-07-31 |
| 2026-09-10 | 8-K | 8-K items 2.02,9.01 | 2026-09-10 |
| 2026-08-28 | DEFA14A | DEFA14A | |
| 2026-08-28 | DEF 14A | DEF 14A | 2026-08-27 |
| 2026-07-27 | 10-K | 10-K | 2026-04-30 |
| 2026-07-27 | 8-K | 8-K items 2.02,9.01 | 2026-07-27 |
| 2026-03-30 | 8-K | 8-K items 5.02,9.01 | 2026-03-24 |
| 2026-03-12 | 10-Q | 10-Q | 2026-01-31 |
| 2026-03-12 | 8-K | 8-K items 2.02,9.01 | 2026-03-12 |
| 2026-01-30 | 4 | FORM 4 | 2025-07-16 |
| 2026-01-30 | 4 | FORM 4 | 2021-11-05 |
| 2026-01-16 | 3 | FORM 3 | 2021-06-09 |
| 2025-12-15 | 10-Q | 10-Q | 2025-10-31 |
| 2025-12-15 | 8-K | 8-K items 2.02,9.01 | 2025-12-15 |
| 2025-11-07 | 4 | FORM 4 | 2025-11-05 |
| 2025-11-07 | 4 | FORM 4 | 2025-11-05 |
| 2025-11-07 | 4 | FORM 4 | 2025-11-05 |
| 2025-11-07 | 4 | FORM 4 | 2025-11-05 |
| 2025-11-07 | 4 | FORM 4 | 2025-11-05 |
| 2025-11-06 | 4 | FORM 4 | 2025-10-30 |
| 2025-10-16 | 8-K | 8-K items 5.07 | 2025-10-16 |
| 2025-09-15 | 10-Q | 10-Q | 2025-07-31 |
| 2025-09-15 | 8-K | 8-K items 2.02,9.01 | 2025-09-15 |
Forms on file (last 1,000): 4 207, 8-K 157, 10-Q 55, 10QSB 39, 3 30, 10-K 18, DEF 14A 16, UPLOAD 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=CSBR (0.002 USD), /gw/filings/filings?ticker=CSBR&form=8-K, /gw/filings/facts?ticker=CSBR&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange